DaShenLin Pharmaceutical Group Co., Ltd.

SHSE:603233 Rapporto sulle azioni

Cap. di mercato: CN¥18.6b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

DaShenLin Pharmaceutical Group Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Guoqiang Ke

Amministratore delegato

CN¥2.3m

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO5.7yrs
Proprietà del CEO0.02%
Durata media del managementNessun dato
Durata media del Consiglio di amministrazione1.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

Sep 30
Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03
DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Aug 20
DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Jun 17
Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Jun 09
Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

May 21
Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

May 06
Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Apr 09
Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

Mar 17
Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

AMMINISTRATORE DELEGATO

Guoqiang Ke (42 yo)

5.7yrs

Mandato

CN¥2,308,800

Compensazione

Mr. Guoqiang Ke is General Manager of DaShenLin Pharmaceutical Group Co., Ltd. from February 28, 2019 and serves as DIrector since February 03, 2023. He was Deputy General Manager of DaShenLin Pharmaceutic...


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Guoqiang Ke
GM & Director1.7yrsCN¥2.31m0.025%
CN¥ 4.6m
Qun Fei Tan
Deputy GM & Director1.7yrsCN¥2.05m0.024%
CN¥ 4.4m
Zhi Hui Chen
Chairman of Supervisory Board & Deputy Director of Human Resources Department - Guangdong Provinceno dataNessun dato0.012%
CN¥ 2.2m
Yun Feng Ke
Chairman of the Boardno dataCN¥2.49m21.3%
CN¥ 4.0b
Guo Liu
Independent Directorno dataCN¥73.40kNessun dato
Zu Yao Su
Independent Directorno dataCN¥80.00kNessun dato
Jie Li
Directorno dataNessun datoNessun dato
Li Ping Lu
Independent Directorno dataCN¥80.00kNessun dato
Jinshu Shi
Staff Supervisorno dataNessun dato0.00055%
CN¥ 102.0k
Wensheng Chen
Supervisor1.7yrsNessun datoNessun dato

1.7yrs

Durata media

54yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 603233 non è considerato esperto (durata media del mandato 1.5 anni), il che suggerisce un nuovo consiglio.